SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed
Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.
Transaction rows by code · counts, not monetary totals
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift
Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete
These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.
SEC issuer · 0001404281Eledon Pharmaceuticals, Inc.
No parent relationship is available in this import; this is not proof of independence.
Eledon Pharmaceuticals, Inc. · former SEC name · 2020-12-16 to 2026-09-04
Novus Therapeutics, Inc. · former SEC name · 2017-02-23 to 2020-12-22
Tokai Pharmaceuticals Inc · former SEC name · 2007-06-18 to 2017-05-04
Revenue in constant purchasing power
USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.
No USD annual revenue periods with complete CPI coverage are available. Non-USD statements are not converted with U.S. CPI.